Intellia Therapeutics Inc (FRA:38I)
€ 13.565 -0.175 (-1.27%) Market Cap: 1.44 Bil Enterprise Value: 903.64 Mil PE Ratio: 0 PB Ratio: 1.53 GF Score: 57/100

Intellia Therapeutics Inc to Discuss Interim Clinical Data from NTLA-2001 Phase 1 Study Transcript

Jun 24, 2022 / 12:00PM GMT
Release Date Price: €47.19 (+3.38%)
Operator

Good morning, and welcome to Intellia's Therapeutics Investor event to discuss the updated interim clinical data from the Phase I study of NTLA-2001. My name is Jason, and I will be your conference operator today. Please be advised that this call is being recorded at the company's request. (Operator Instructions) I will now turn the conference over to Ian Karp, Senior Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed.

Ian Karp
Intellia Therapeutics, Inc. - SVP of IR & Corporate Communications

Thank you, operator, and good morning, everyone. I'm pleased to welcome you to Intellia's investor event featuring updated interim data from the Phase I clinical trial of NTLA-2001. Earlier today, Intellia issued a press release detailing these results. This release, along with the accompanying presentation can be found on the Investors & Media section of Intellia's website at intelliatx.com.

As a reminder, this call is being broadcast live and a replay of the event will be archived on the company's website. At

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot